Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up.

Connolly AM, Florence JM, Zaidman CM, Golumbek PT, Mendell JR, Flanigan KM, Karachunski PI, Day JW, McDonald CM, Darras BT, Kang PB, Siener CA, Gadeken RK, Anand P, Schierbecker JR, Malkus EC, Lowes LP, Alfano LN, Johnson L, Nicorici A, Kelecic JM, Quigley J, Pasternak AE, Miller JP; MDA-DMD Clinical Research Network.

Muscle Nerve. 2016 Oct;54(4):681-9. doi: 10.1002/mus.25089. Epub 2016 May 10.

PMID:
26930423
2.

Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy.

Connolly AM, Malkus EC, Mendell JR, Flanigan KM, Miller JP, Schierbecker JR, Siener CA, Golumbek PT, Zaidman CM, Mcdonald CM, Johnson L, Nicorici A, Karachunski PI, Day JW, Kelecic JM, Lowes LP, Alfano LN, Darras BT, Kang PB, Quigley J, Pasternak AE, Florence JM; MDA DMD Clinical Research Network.

Muscle Nerve. 2015 Apr;51(4):522-32. doi: 10.1002/mus.24346. Epub 2015 Feb 11.

3.

Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.

Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, Siener CA, Wulf CO, Anand P, Golumbek PT, Zaidman CM, Philip Miller J, Lowes LP, Alfano LN, Viollet-Callendret L, Flanigan KM, Mendell JR, McDonald CM, Goude E, Johnson L, Nicorici A, Karachunski PI, Day JW, Dalton JC, Farber JM, Buser KK, Darras BT, Kang PB, Riley SO, Shriber E, Parad R, Bushby K, Eagle M; MDA DMD Clinical Research Network.

Neuromuscul Disord. 2013 Jul;23(7):529-39. doi: 10.1016/j.nmd.2013.04.005. Epub 2013 May 28.

4.

Developing normalized strength scores for neuromuscular research.

Andres PL, English R, Mendoza M, Florence J, Malkus E, Schierbecker J, Siener C, Malspeis S, Schoenfeld DA, Munsat TL, Cudkowicz ME.

Muscle Nerve. 2013 Feb;47(2):177-82. doi: 10.1002/mus.23516. Epub 2012 Nov 21.

PMID:
23168880
5.

Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation.

Lopate G, Baloh RH, Al-Lozi MT, Miller TM, Fernandes Filho JA, Ni O, Leston A, Florence J, Schierbecker J, Allred P.

Amyotroph Lateral Scler. 2010;11(1-2):232-6. doi: 10.3109/17482960902898069.

PMID:
20184521
6.

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.

Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M.

Neurology. 2005 Dec 13;65(11):1834-6.

PMID:
16344537
7.

High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.

Connolly AM, Schierbecker J, Renna R, Florence J.

Neuromuscul Disord. 2002 Dec;12(10):917-25.

PMID:
12467746
8.

Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy.

Florence JM, Pandya S, King WM, Robison JD, Baty J, Miller JP, Schierbecker J, Signore LC.

Phys Ther. 1992 Feb;72(2):115-22; discussion 122-6.

PMID:
1549632
9.

Randomized, double-blind trial of mazindol in Duchenne dystrophy.

Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Miller PJ, Mandel S, Florence J, Schierbecker J, Kaiser KK, et al.

Muscle Nerve. 1990 Dec;13(12):1169-73.

PMID:
2266990
10.

Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy.

Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, King WM, Pandya S, Robison J, Schierbecker J, et al.

Neurology. 1989 Apr;39(4):475-81.

PMID:
2927672

Supplemental Content

Loading ...
Support Center